Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 469 for:    OCD

Rapid Non-Invasive Brain Stimulation for OCD (oTMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03404609
Recruitment Status : Active, not recruiting
First Posted : January 19, 2018
Last Update Posted : June 29, 2020
Sponsor:
Information provided by (Responsible Party):
Carolyn Rodriguez, Stanford University

Brief Summary:
The purpose of this study is to understand how cortical stimulation affects Obsessive-Compulsive Disorder (OCD) symptoms.

Condition or disease Intervention/treatment Phase
OCD Device: MagPro X100 by MagVenture Not Applicable

Detailed Description:
Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This study aims to understand how cortical stimulation affects Obsessive-Compulsive Disorder

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rapid Non-Invasive Brain Stimulation for OCD (oTMS)
Actual Study Start Date : August 25, 2018
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 1, 2022

Arm Intervention/treatment
Experimental: rTMS
Participants in the rTMS group will receive MagPro X100 by MagVenture (Active) cortical stimulation condition.
Device: MagPro X100 by MagVenture
Participants in the rTMS group will receive MagPro X100 by MagVenture cortical stimulation condition.




Primary Outcome Measures :
  1. Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. [ Time Frame: Up to two weeks ]
    Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-80
  • Primary diagnosis of OCD
  • Sufficient severity of OCD symptoms
  • Capacity to provide informed consent

Exclusion Criteria:

  • Psychiatric or medical conditions or medications that make participation unsafe
  • Pregnant or nursing females
  • Previous exposure to TMS or ECT
  • History of any implanted device or psychosurgery
  • Presence of metallic device or dental braces

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03404609


Locations
Layout table for location information
United States, California
Stanford University
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Carolyn Rodriguez, MD, PhD Stanford University
Study Director: Nolan Williams, MD Stanford University
Additional Information:
Layout table for additonal information
Responsible Party: Carolyn Rodriguez, Assistant Professor, Stanford University
ClinicalTrials.gov Identifier: NCT03404609    
Other Study ID Numbers: 43421
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: June 29, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No